Combination strategies using [225Ac]Macropa-PEG4-7065 with existing AML therapies such as hypomethylating agents (e.g., azacitidine) or BCL-2 inhibitors (e.g., venetoclax) may further enhance therapeutic efficacy. This evidence concerns the gene BCL2 and acute myeloid leukemia.